FMDV 3C: Difference between revisions

From Proteopedia
Jump to navigationJump to search
No edit summary
No edit summary
Line 10: Line 10:


== Relevance ==
== Relevance ==
 
Vaccines against FMDV are used where the disease is endemic, however, vaccination is not permitted in many countries due to the potential risk for the escape of FMDV. Therefore, there has been interest in producing empty capsid particles for use of potential vaccines against FMD.
Unfortunately, there has been a number of challenges in this synthetic approach, which can be attributed 3C's toxicity to mammalian cells (which is responsible for processing P1-2A in creating the capsid proteins) 
To solve this conundrum, different strategies must be analyzed to determine an optimal system for the production of FMDV empty capsid proteins with a limited amount of 3C protease that can stll process P1-2A, with out adverse expression effects.
== Structural highlights ==
== Structural highlights ==
<scene name='70/702408/Fmdv_3c_protease_type_a10/6'>FMDV 3C Protease</scene>
<scene name='70/702408/Fmdv_3c_protease_type_a10/6'>FMDV 3C Protease</scene>

Revision as of 14:29, 14 July 2015

FMDV 3C Protease

FMDV 3C Protease Type A10

Drag the structure with the mouse to rotate

References

references [1]

  1. Hanson, R. M., Prilusky, J., Renjian, Z., Nakane, T. and Sussman, J. L. (2013), JSmol and the Next-Generation Web-Based Representation of 3D Molecular Structure as Applied to Proteopedia. Isr. J. Chem., 53:207-216. doi:https://dx.doi.org/10.1002/ijch.201300024

Proteopedia Page Contributors and Editors (what is this?)

Erica Martel, Michal Harel, Alexander Berchansky